Intellia and regeneron announce initial data from the cardiomyopathy arm of ongoing phase 1 study of ntla-2001, an investigational crispr therapy for the treatment of transthyretin (attr) amyloidosis

Interim data from the cardiomyopathy arm of the phase 1 study of ntla-2001 showed deep and sustained mean serum transthyretin (ttr) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28  ntla-2001 was generally well-tolerated at both dose levels intellia to discuss data at investor event today, friday, september 16, at 8:00 a.m. et cambridge, mass.
REGN Ratings Summary
REGN Quant Ranking